Neuroendocrine tumour
PRRT Versus PRRT Plus Chemotherapy in GEP NET (PReCedeNT Trial)
Where to go
2 hospitals in India taking patients for this trial.
Registry summary (technical)
Neuroendocrine tumours (NETs), better defined as neoplasms (NENs), are a heterogeneous group of neoplasms that range from well-differentiated tumours to more aggressive carcinomas. Peptide receptor radionuclide therapy (PRRT) with Lutetium-177 DOTATATE is the established standard of care for patients with well-differentiated metastatic or locally advanced GEP-NETs. It has demonstrated a significant improvement in outcomes compared to Octreotide LAR, both as a first-line and second-line treatment approach, following the results of NETTER-1 and NETTER-2 trials, respectively. ENETS guidelines rec…
Sponsor: Tata Memorial Hospital
NCT07185672 on ClinicalTrials.gov
Last updated on the registry 22 Sep 2025 · read by us 20 Oct 2026